Journal Mobile Options
Table of Contents
Vol. 30, No. 1, 2009
Issue release date: July 2009
Section title: Original Report: Laboratory Investigation
Am J Nephrol 2009;30:1–11
(DOI:10.1159/000195722)

Amelioration of Diabetic Nephropathy in OLETF Rats by Prostaglandin I2 Analog, Beraprost Sodium

Watanabe M. · Nakashima H. · Mochizuki S. · Abe Y. · Ishimura A. · Ito K. · Fukushima T. · Miyake K. · Ogahara S. · Saito T.
aDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, bDepartment of Pathology, Tohoku University Hospital, Sendai, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Report: Laboratory Investigation

Received: 9/4/2008
Accepted: 11/27/2008
Published online: 1/22/2009
Issue release date: July 2009

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 1

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN

Abstract

Background: Strict control of blood glucose and blood pressure levels sometimes fails to delay the development of diabetic nephropathy, and an effective therapy is not yet available. The present study aimed to examine whether the prostaglandin I2 analog beraprost sodium (BPS) ameliorates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rat. Method: Fifty-week-old OLETF rats were divided into three groups according to treatment; 400 μg/kg body weight (BW) BPS, 200 μg/kg BW BPS, and 0.9% saline administration. Kidney histology, index of glomerulosclerosis, and glomerular volume were determined, and urine and serum chemistry were assessed. Results: The values for urine protein excretion and serum blood urea nitrogen in BPS-treated rats were significantly lower than those in untreated rats. In rats treated with 400 μg/kg BW BPS, neither sclerotic changes nor inflammatory cell infiltration were observed. Index of glomerulosclerosis and glomerular volume were also significantly reduced compared with untreated rats. Intriguingly, BPS reduced the level of serum triglyceride. In the glomerulus of treated rats, advanced glycation end product formation and macrophage influx were suppressed in a dose-dependent manner. Conclusion: These findings indicate that BPS has a therapeutic effect on diabetic nephropathy in the OLETF rat, which suggests a potential application of this drug in the treatment of human diabetic nephropathy.


  

Author Contacts

Hitoshi Nakashima, MD, PhD
Division of Nephrology and Rheumatology, Department of Internal Medicine
Fukuoka University, Faculty of Medicine
Jonan-ku, Fukuoka 814-0180 (Japan)
Tel. +81 92 801 1011, Fax +81 92 873 8008, E-Mail hnakashi@fukuoka-u.ac.jp

  

Article Information

Received: September 4, 2008
Accepted: November 27, 2008
Published online: January 22, 2009
Number of Print Pages : 11
Number of Figures : 4, Number of Tables : 1, Number of References : 59

  

Publication Details

American Journal of Nephrology

Vol. 30, No. 1, Year 2009 (Cover Date: July 2009)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250-8095 (Print), eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Article / Publication Details

First-Page Preview
Abstract of Original Report: Laboratory Investigation

Received: 9/4/2008
Accepted: 11/27/2008
Published online: 1/22/2009
Issue release date: July 2009

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 1

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.